Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

A Retrospective Cohort Study of Growth in the First Two Years of Life in Preterm Infants with Cystic Fibrosis.

Holland KJ, Slaven JE, Ren CL, Sanders DB, Bennett WE Jr.

J Pediatr Gastroenterol Nutr. 2019 Sep 23. doi: 10.1097/MPG.0000000000002513. [Epub ahead of print]

PMID:
31567647
2.

Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia.

Raja SM, Sanders DB, Juel VC, Harati Y, Smith AG, Pascuzzi R, Richman DP, Wu A, Aleš KL, Jacobus LR, Jacobus DP, Guptill JT; DAPPER Study Team.

Muscle Nerve. 2019 Sep;60(3):292-298. doi: 10.1002/mus.26625. Epub 2019 Jul 18.

PMID:
31269226
3.

Predictors of pulmonary exacerbation treatment in cystic fibrosis.

Sanders DB, Ostrenga JS, Rosenfeld M, Fink AK, Schechter MS, Sawicki GS, Flume PA, Morgan WJ.

J Cyst Fibros. 2019 Jun 27. pii: S1569-1993(18)30763-X. doi: 10.1016/j.jcf.2019.06.008. [Epub ahead of print]

PMID:
31257102
4.

Standards for quantification of EMG and neurography.

Stålberg E, van Dijk H, Falck B, Kimura J, Neuwirth C, Pitt M, Podnar S, Rubin DI, Rutkove S, Sanders DB, Sonoo M, Tankisi H, Zwarts M.

Clin Neurophysiol. 2019 Sep;130(9):1688-1729. doi: 10.1016/j.clinph.2019.05.008. Epub 2019 Jun 10. Review.

5.

Guidelines for single fiber EMG.

Sanders DB, Arimura K, Cui L, Ertaş M, Farrugia ME, Gilchrist J, Kouyoumdjian JA, Padua L, Pitt M, Stålberg E.

Clin Neurophysiol. 2019 Aug;130(8):1417-1439. doi: 10.1016/j.clinph.2019.04.005. Epub 2019 Apr 27. Review.

6.

Neuromuscular transmission in myopathies.

Sanders DB.

Muscle Nerve. 2019 Jul;60(1):E8. doi: 10.1002/mus.26501. Epub 2019 May 13. No abstract available.

PMID:
31049975
7.

Author Correction: A population of luminous accreting black holes with hidden mergers.

Koss MJ, Blecha L, Bernhard P, Hung CL, Lu JR, Trakhtenbrot B, Treister E, Weigel A, Sartori LF, Mushotzky R, Schawinski K, Ricci C, Veilleux S, Sanders DB.

Nature. 2019 Apr;568(7750):E1. doi: 10.1038/s41586-018-0827-2.

PMID:
30899103
8.

Cystic fibrosis in El Salvador.

Hinds DM, Sanders DB, Slaven JE, Romero M, Davis SD, Stevens JC.

Pediatr Pulmonol. 2019 Apr;54(4):369-371. doi: 10.1002/ppul.24232. Epub 2019 Jan 29. No abstract available.

PMID:
30694614
9.

Secondhand smoke alters arachidonic acid metabolism and inflammation in infants and children with cystic fibrosis.

Kopp BT, Thompson R, Kim J, Konstan R, Diaz A, Smith B, Shrestha C, Rogers LK, Hayes D Jr, Tumin D, Woodley FW, Ramilo O, Sanders DB, Groner JA, Mejias A.

Thorax. 2019 Mar;74(3):237-246. doi: 10.1136/thoraxjnl-2018-211845. Epub 2019 Jan 19.

PMID:
30661024
10.

Developmental Milestones in Pediatric Research: A Case for Including Efficacy as Part of Interventional Trials in Infants with Cystic Fibrosis.

Sanders DB, Nichols DP.

Am J Respir Crit Care Med. 2019 May 15;199(10):1181-1182. doi: 10.1164/rccm.201811-2103ED. No abstract available.

11.

A population of luminous accreting black holes with hidden mergers.

Koss MJ, Blecha L, Bernhard P, Hung CL, Lu JR, Trakhtenbrot B, Treister E, Weigel A, Sartori LF, Mushotzky R, Schawinski K, Ricci C, Veilleux S, Sanders DB.

Nature. 2018 Nov;563(7730):214-216. doi: 10.1038/s41586-018-0652-7. Epub 2018 Nov 7. Erratum in: Nature. 2019 Apr;568(7750):E1.

PMID:
30405225
12.

Quantitative chest computerized tomography and FEV1 equally identify pulmonary exacerbation risk in children with cystic fibrosis.

Sanders DB, Li Z, Parker-McGill K, Farrell P, Brody AS.

Pediatr Pulmonol. 2018 Oct;53(10):1369-1377. doi: 10.1002/ppul.24144. Epub 2018 Aug 29.

PMID:
30160050
13.

Reply.

Nandedkar SD, Sanders DB, Hobson-Webb LD, Billlakota S, Barkhaus PE, Stalberg EV.

Muscle Nerve. 2018 Oct;58(4):E31-E32. doi: 10.1002/mus.26198. Epub 2018 Sep 18. No abstract available.

PMID:
30043996
14.

Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.

Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, Zvartau-Hind M, Bril V; BEL115123 Study Group.

Neurology. 2018 Apr 17;90(16):e1425-e1434. doi: 10.1212/WNL.0000000000005323. Epub 2018 Mar 21.

15.

Problems in Comparing Jitter Values Obtained with Voluntary Activation and Electrical Stimulation.

Stålberg E, Kouyoumdjian JA, Paiva GP, Yanaze LL, Sanders DB.

J Neuromuscul Dis. 2018;5(2):225-230. doi: 10.3233/JND-170289.

PMID:
29614693
16.

Reply.

Sanders DB, Harati Y, Juel VC, Lou JS, Marburger T, Pascuzzi RM, Peltier AC, Richman DP, Smith AG.

Muscle Nerve. 2018 May;57(5):E130-E131. doi: 10.1002/mus.26089. Epub 2018 Mar 1. No abstract available.

PMID:
29406616
17.

Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis.

Sanders DB, Zhang Z, Farrell PM, Lai HJ; Wisconsin CF Neonatal Screening Group.

J Cyst Fibros. 2018 Jul;17(4):528-535. doi: 10.1016/j.jcf.2018.01.006. Epub 2018 Feb 1.

18.

Developing treatment guidelines for myasthenia gravis.

Sanders DB, Wolfe GI, Narayanaswami P; MGFA Task Force on MG Treatment Guidance.

Ann N Y Acad Sci. 2018 Jan;1412(1):95-101. doi: 10.1111/nyas.13537. Review.

PMID:
29381223
19.

Comparative effectiveness clinical trials to advance treatment of myasthenia gravis.

Guptill JT, Raja S, Sanders DB, Narayanaswami P.

Ann N Y Acad Sci. 2018 Feb;1413(1):69-75. doi: 10.1111/nyas.13582. Epub 2018 Jan 28. Review.

PMID:
29377158
20.

3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.

Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, Lou JS, Pascuzzi RM, Richman DP, Xie T, Demmel V, Jacobus LR, Aleš KL, Jacobus DP; Dapper Study Team.

Muscle Nerve. 2018 Apr;57(4):561-568. doi: 10.1002/mus.26052. Epub 2018 Feb 2.

21.

Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.

Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH; STOP Study Group.

Contemp Clin Trials. 2018 Jan;64:35-40. doi: 10.1016/j.cct.2017.11.012. Epub 2017 Nov 21.

22.

Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Heltshe SL, Khan U, Beckett V, Baines A, Emerson J, Sanders DB, Gibson RL, Morgan W, Rosenfeld M.

J Cyst Fibros. 2018 May;17(3):341-347. doi: 10.1016/j.jcf.2017.10.008. Epub 2017 Oct 28.

23.

Pitfalls and errors in measuring jitter.

Stålberg E, Sanders DB, Kouyoumdjian JA.

Clin Neurophysiol. 2017 Nov;128(11):2233-2241. doi: 10.1016/j.clinph.2017.09.001. Epub 2017 Sep 21. Review.

PMID:
29017138
24.

Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.

Sanders DB, Zhao Q, Li Z, Farrell PM.

Pediatr Pulmonol. 2017 Oct;52(10):1268-1275. doi: 10.1002/ppul.23765. Epub 2017 Sep 7.

25.

Poor recovery from a pulmonary exacerbation does not lead to accelerated FEV1 decline.

Sanders DB, Li Z, Zhao Q, Farrell PM.

J Cyst Fibros. 2017 Jul 29. pii: S1569-1993(17)30818-4. doi: 10.1016/j.jcf.2017.07.003. [Epub ahead of print]

26.

Reliability of the triple-timed up-and-go test.

Sanders DB, Guptill JT, Aleš KL, Hobson-Webb LD, Jacobus DP, Mahmood R, Massey JM, Pittman MM, Prather K, Raja SM, Yow E, Juel VC.

Muscle Nerve. 2018 Jan;57(1):136-139. doi: 10.1002/mus.25700. Epub 2017 Jun 6.

27.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.

28.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators.

J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.

29.

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.

VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):607-615. doi: 10.1016/j.jcf.2017.04.004. Epub 2017 Apr 21.

30.

Marked clinical and jitter improvement after eculizumab in refractory myasthenia.

Juel VC, Sanders DB, Hobson-Webb LD, Massey JM, Guptill JT, O'Brien F, Wang JJ, Howard JF Jr.

Muscle Nerve. 2017 Sep;56(3):E16-E18. doi: 10.1002/mus.25620. Epub 2017 Jun 5. No abstract available.

PMID:
28214342
31.

The extrapolated reference values procedure: Theory, algorithm, and results in patients and control subjects.

Nandedkar SD, Sanders DB, Hobson-Webb LD, Billakota S, Barkhaus PE, Stålberg EV.

Muscle Nerve. 2018 Jan;57(1):90-95. doi: 10.1002/mus.25606. Epub 2017 Apr 10.

PMID:
28181271
32.

Author response: International consensus guidance for management of myasthenia gravis: Executive summary.

Sanders DB, Wolfe GI, Narayanaswami P.

Neurology. 2017 Jan 31;88(5):505-506. doi: 10.1212/WNL.0000000000003570. No abstract available.

PMID:
28138082
33.

Diagnosis of Cystic Fibrosis in Screened Populations.

Farrell PM, White TB, Howenstine MS, Munck A, Parad RB, Rosenfeld M, Sommerburg O, Accurso FJ, Davies JC, Rock MJ, Sanders DB, Wilschanski M, Sermet-Gaudelus I, Blau H, Gartner S, McColley SA.

J Pediatr. 2017 Feb;181S:S33-S44.e2. doi: 10.1016/j.jpeds.2016.09.065.

34.

Does change in neuromuscular jitter predict or correlate with clinical change in MG?

Sanders DB, Massey JM.

Muscle Nerve. 2017 Jul;56(1):45-50. doi: 10.1002/mus.25440. Epub 2017 Feb 15.

PMID:
27759891
35.

Background and Epidemiology.

Sanders DB, Fink AK.

Pediatr Clin North Am. 2016 Aug;63(4):567-84. doi: 10.1016/j.pcl.2016.04.001. Review.

36.

International consensus guidance for management of myasthenia gravis: Executive summary.

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P.

Neurology. 2016 Jul 26;87(4):419-25. doi: 10.1212/WNL.0000000000002790. Epub 2016 Jun 29. Review.

37.

Factors affecting outcome in myasthenia gravis.

Andersen JB, Gilhus NE, Sanders DB.

Muscle Nerve. 2016 Dec;54(6):1041-1049. doi: 10.1002/mus.25205.

PMID:
27251303
38.

International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r.

Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, Bril V, Barnett C, Guptill JT, Sanders DB, Hobson-Webb L, Juel VC, Massey J, Gable KL, Silvestri NJ, Wolfe G, Cutter G, Nagane Y, Murai H, Masuda M, Farrugia ME, Carmichael C, Birnbaum S, Hogrel JY, Nafissi S, Fatehi F, Ou C, Liu W, Conaway M.

Muscle Nerve. 2016 Dec;54(6):1015-1022. doi: 10.1002/mus.25198. Epub 2016 Nov 7.

PMID:
27220659
39.

Lambert-Eaton myasthenia?

Sanders DB.

Muscle Nerve. 2016 Mar;53(3):495. doi: 10.1002/mus.25001. Epub 2016 Jan 23. No abstract available.

PMID:
26661270
40.

ATS Core Curriculum 2015: Part III. Pediatric Pulmonary Medicine.

Boyer D, Nevin M, Thomson CC, Sanders DB, Alexiou S, Goldfarb SB, Nicholas JL, Thacker PG, Coverstone AM, Faro A, Cheng G, Majid A, Moore PE.

Ann Am Thorac Soc. 2015 Nov;12(11):1688-96. doi: 10.1513/AnnalsATS.201506-322CME. No abstract available.

41.

The epidemiology of poor outcomes after pulmonary exacerbations.

Sanders DB.

J Cyst Fibros. 2015 Nov;14(6):679-80. doi: 10.1016/j.jcf.2015.10.002. Epub 2015 Oct 21. No abstract available.

42.

Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years.

Sanders DB, Fink A, Mayer-Hamblett N, Schechter MS, Sawicki GS, Rosenfeld M, Flume PA, Morgan WJ.

J Pediatr. 2015 Nov;167(5):1081-8.e1. doi: 10.1016/j.jpeds.2015.07.044. Epub 2015 Sep 2.

43.

Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.

Sanders DB, Emerson J, Ren CL, Schechter MS, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group.

Ann Am Thorac Soc. 2015 Aug;12(8):1170-6. doi: 10.1513/AnnalsATS.201504-198OC.

44.

Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.

Benatar M, Mcdermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, Hehir M, Juel V, Katzberg H, Tawil R; Muscle Study Group (MSG).

Muscle Nerve. 2016 Mar;53(3):363-9. doi: 10.1002/mus.24769. Epub 2016 Jan 27.

45.

Reference values for jitter recorded by concentric needle electrodes in healthy controls: A multicenter study.

Stålberg E, Sanders DB, Ali S, Cooray G, Leonardis L, Löseth S, Machado F, Maldonado A, Martinez-Aparicio C, Sandberg A, Smith B, Widenfalk J, Aris Kouyoumdjian J.

Muscle Nerve. 2016 Mar;53(3):351-62. doi: 10.1002/mus.24750. Epub 2015 Nov 13.

PMID:
26112058
46.

Stimulated jitter in infant botulism.

Sanders DB.

Muscle Nerve. 2015 Oct;52(4):691-2. doi: 10.1002/mus.24737. Epub 2015 Jul 1. No abstract available.

PMID:
26096260
47.

Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.

Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group.

Pediatr Pulmonol. 2015 Aug;50(8):763-70. doi: 10.1002/ppul.23217. Epub 2015 Jun 9.

48.

Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening.

Ren CL, Fink AK, Petren K, Borowitz DS, McColley SA, Sanders DB, Rosenfeld M, Marshall BC.

Pediatrics. 2015 Jun;135(6):e1386-92. doi: 10.1542/peds.2014-3698. Epub 2015 May 11.

49.

Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA.

Thorax. 2016 Mar;71(3):223-9. doi: 10.1136/thoraxjnl-2014-206750. Epub 2015 Apr 24.

50.

Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, Howard JF Jr, Scuderi F, Bartoccioni E, Evoli A, Weinhold KJ.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 26;2(2):e77. doi: 10.1212/NXI.0000000000000077. eCollection 2015 Apr.

Supplemental Content

Loading ...
Support Center